Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of vosoritide in children with hypochondroplasia
jRCT2051240179Phase 3Completed
- Sponsor
- BioMarin Pharmaceutical Inc.
- Start
- Dec 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
01
Overview
Phase 3, randomised, double-blind trial in hypochondroplasia (HCH) comparing Vosoritide with Placebo (2 arms). Primary endpoint: Change from baseline in annualized growth velocity at Week 52 versus placebo. Started Dec 2024; status: completed.
02
Drugs
vosoritide
03
Conditions
hypochondroplasia (HCH)
Beyond the preview
Go deeper on jRCT2051240179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240179.